Poster Presentation The 16th Australian Peptide Conference 2025

Developing a High-Throughput Screen for Conotoxin Agonists of the GABAB Receptor (#120)

Liam Jackson 1
  1. University of Queensland, St Lucia, QUEENSLAND, Australia

Neuropathic pain is a major and undertreated form of chronic pain, originating from
pathology of the nervous system. Currently, its global market is estimated to be several
billions of dollars a year as current treatment options lack efficacy whilst producing
unwanted side effects, tolerance and addiction [1]. A potential source of therapeutics
are disulfude-rich peptide neurotoxins derived from the venom of marine cone snails,
known as conotoxins. The

  1. [1] D. Bouhassira and N. Attal, “Translational neuropathic pain research: A clinical perspective,” Neuroscience, pp. 27-35, 2016.
  2. [2] N. Satkunanathan and et al, “ Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones,” Brain Res, vol. 1059, no. 2, pp. 149-158, 2005.
  3. [3] M. Vincler and J. McIntosh, “Targeting the alpha9alpha10 nicotinic acetylcholine receptor to treat severe pain,” Expert Opin Ther Targets, vol. 11, no. 7, pp. 891- 897, 2007.